Publication | Closed Access

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

Neurodegenerative DiseasesGeriatric NeurologyAlzheimer's DiseaseImmunologyClinical TrialsActive Aβ ImmunotherapyVascular DementiaAntibody ResponseNeurologyAging-associated DiseaseFirst-in-human StudyImmunotherapyMedicineNeuroimmunologyTreatmentProtective MechanismsHealth Sciences